Aktuellt
SENASTE
IRLAB Therapeutics has successfully completed the second and final of two pre-determined safety and data integrity reviews for its ongoing Phase IIb clinical trial (React PD) for pirepemat. The study will assess the ability to improve balance and reduce falls in patients with Parkinson’s disease (PD-Falls). The independent data and safety monitoring board (DSMB) has unanimously recommended that the React PD study should continue without any changes. Hence, and in line with previous guidance, patient recruitment remains on track to be completed in Q324, and we expect top-line results to be shared in Q424 or Q125, which would be after the three-month treatment period, follow-up visits and required data analyses.
LÄS MER
